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INTRODUCTION
The genus Mycobacterium has more than 100 well-charac-
terized species (1), and with the exception of Mycobacterium
tuberculosis and M. leprae, the other members are normal inhab-
itants of natural waters, drinking waters, and soils. These
mycobacteria are now generally called nontuberculous myco-
bacteria (NTM). Previous names for this group of organisms
included environmental mycobacteria, opportunistic mycobac-
teria, atypical mycobacteria, or mycobacteria other than tuber-
culosis. Human disease due to NTMs is classified into four
distinct clinical syndromes: chronic pulmonary disease, lym-
phadenitis, cutaneous disease, and disseminated disease. Of
these, chronic pulmonary disease is most commonly encoun-
tered clinically (2, 3).
In Korea, NTM pulmonary disease shows an increasing
prevalence due to the increasing numbers of immunocom-
petent patients with or without pre-existing lung disease
(4, 5). In fact, many referral centers have reported increasing
numbers of patients with NTM pulmonary disease over recent
years. Moreover, in the future it appears that patients with
NTM pulmonary disease will be as commonly encountered
in daily clinical practice, as patients with pulmonary tuber-
culosis are today.
NTM infections are thus posing an increasing challenge
to physicians in terms of diagnosis and treatment. The clin-
ical and radiographic manifestations of NTM pulmonary
disease are variable and often subtle, to the extent that they
may be indistinguishable from those of tuberculosis. More-
over, the treatment of patients with NTM pulmonary disease
requires more individualization than tuberculosis patients.
This individualization is dependent on the species of mycobac-
teria recovered, the site and severity of infection, antimicro-
bial drug susceptibility test results, underlying diseases, and
the patient’s general condition. In addition, the requirement
for protracted treatment, side effects, the cost of therapy, and
frequent relapses all hinder successful treatment (2, 3).
In this article, we review the epidemiology, the clinical
and radiographic manifestations, and the diagnosis and treat-
ment of NTM pulmonary disease with an emphasis on human
immunodeficiency virus (HIV)-negative patients.
EPIDEMIOLOGY
NTM organisms are ubiquitously distributed in the envi-
ronment, and it had been well documented that reservoirs
for most of these infections by M. avium, M. intracellulare,
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The incidence of pulmonary disease caused by nontuberculous mycobacteria (NTM)
appears to be increasing worldwide. In Korea, M. avium complex and M. abscessus
account for most of the pathogens encountered, whilst M. kansasii is a relatively
uncommon cause of NTM pulmonary diseases. NTM pulmonary disease is highly
complex in terms of its clinical presentation and management. Because its clinical
features are indistinguishable from those of pulmonary tuberculosis and NTMs are
ubiquitous in the environment, the isolation and identification of causative organisms
are mandatory for diagnosis, and some specific diagnostic criteria have been pro-
posed. The treatment of NTM pulmonary disease depends on the infecting species,
but decisions concerning the institution of treatment are never easy. Treatment re-
quires the use of multiple drugs for 18 to 24 months. Thus, treatment is expensive,
often has significant side effects, and is frequently not curative. Therefore, clinicians
should be confident that there is sufficient pathology to warrant prolonged, multidrug
treatment regimens. In all of the situations, outcomes can be best optimized only
when clinicians, radiologists, and laboratories work cooperatively.
Key Words : Mycobacteria, Atypical; Mycobacterium avium Complex; Mycobacterium abscessus; Mycobac-
terium kansasii, Epidemiology; Diagnosis; Antibiotics, Antitubercular; Korea
Received : 12 September 2005
Accepted : 31 October 2005
� REVIEW �914 W.-J. Koh, O.J. Kwon, K.S. Lee
M. fortuitum, M. chelonae, and M. abscessus are probably soil,
natural waters, and the aerosols of these (6, 7). In addition,
tap water, ice prepared from tap water, processed tap water
for dialysis, and swimming pools and their aerosols are all a
source of NTM infection. Local tap water and hospital water
tanks have been identified as sources of M. kansasii infection,
which is not found in natural waters or soil (6, 7).
Unlike infection by M. tuberculosis, person-to-person trans-
mission is thought not to occur, and thus the isolation of
infected individuals is not required. It is generally assumed
that most are infected by environmental NTM. Of the many
possible sources of infection, airborne NTM may play an
important role in respiratory disease, whereas ingestion is
likely to be an important source of infection for children with
NTM cervical lymphadenitis and for the majority of HIV-
infected patients, in whom M. avium dissemination begins
as gastrointestinal colonization. In addition, the direct inoc-
ulation of NTM organisms from water or some other mate-
rial is likely to be a source of infection for those with a soft
tissue infection (6, 7). 
The most frequent pathogens are M. avium complex (MAC),
M. kansasii, M. abscessus, M. xenopi, and M. malmoense in NTM
pulmonary disease (2, 3, 8). Unlike tuberculosis, NTM dis-
eases are not required to be reported to public health author-
ities in most countries, including Korea, and therefore, pre-
cise incidence and prevalence data are not available. However,
on the basis of laboratory reports and surveillance studies,
there appears to be marked geographic variability both in
the prevalence of disease and in the mycobacterial species
responsible for it (8). NTM pulmonary disease in the United
States is most commonly due to MAC, followed by M. kansasii
(2). In the United Kingdom, M. kansasii is the most com-
mon pathogen in England and Wales, whereas M. malmoense
is most common in Scotland, and M. xenopi in southeast Eng-
land (3). In Japan, MAC is the most common cause of NTM
pulmonary disease, followed by M. kansasii (9). 
It is well-known from studies in developed countries that
the relative importance of NTM pulmonary disease tends to
increase, as the incidence of tuberculosis decreases. And, the
reported cases with NTM pulmonary disease has continued
to rise in Korea since the early 1990s, whereas the incidence
of tuberculosis has decreased remarkably over the past 30 yr
(4). Before the early 1990s, more than 97-98% of clinical
isolates from sputum specimens contained M. tuberculosis in
Korea (10-12). However, after the late 1990s, NTM was
isolated from 20-30% of all clinical specimens submitted to
mycobacterial laboratory in some Korean referral hospitals
(13, 14). 
Traditionally, tuberculosis case detection is primarily based
on the microscopic examination of sputum for acid-fast bacilli
(AFB), although a definitive diagnosis of pulmonary tuber-
culosis normally requires the isolation of M. tuberculosis. In
Korea, patients with AFB smear-positive sputum specimens
were previously automatically diagnosed as having pulmonary
tuberculosis, and antituberculosis treatment was promptly
administered according to the guidelines set by the Nation-
al Tuberculosis Program (15, 16). This is not the case nowa-
days, even in Korea, because AFB seen on a smear test may
represent either M. tuberculosis or NTM. We recently analyzed
data from 1,328 AFB smear-positive consecutive sputum
specimens collected between 1998 and 2001 at the Samsung
Medical Center. NTM were recovered from 9.1% (121/1,328)
of these specimens, and from 8.1% (50/616) of patients with
smear-positive sputum (17). Lee et al. also reported that NTM
were recovered from 10.6% (76/719) AFB smear-positive
respiratory specimens at the Asan Medical Center (a positive
smear was defined as one with ≥1 AFB in 100 high-power
fields) (14). In addition, NTM were isolated from 7.3% of
4,506 AFB smear-positive specimens that were submitted
to the Korean Institute of Tuberculosis between 2001 and
2002 from various institutions, including public health cen-
ters and private hospitals (17). These results suggest that a
substantial proportion of patients with AFB smear-positive
sputum specimens in Korea actually have NTM pulmonary
disease, rather than pulmonary tuberculosis.
The Korean Institute of Tuberculosis started testing for
species identification of NTM from 1981, and the first case
of MAC pulmonary disease in Korea was reported in 1981
(18) and other sporadic reports of lung disease caused by
MAC (19), M. fortuitum (19), and M. abscessus (20) followed
in the early 1980s. Subsequently, a national survey by the
Korean Academy of Tuberculosis and Respiratory Diseases
was performed in 1995 using the clinical and laboratory data
of 158 patients from whom NTM had been isolated, and
requested for species identification to the Korean Institute of
Tuberculosis from 1981 to 1994 (21). This survey found that
66% of NTM isolates were MAC, 13% were M. fortuitum,
9% were M. chelonae complex, and 12% were other NTMs.
Most isolates that were identified as M. chelonae complex are
assumed to be M. abscessus, because the Korean Institute of
Tuberculosis reported M. abscessus isolates as M. chelonae com-
plex without further species identification until 2000. Unfor-
tunately, this survey did not use specific diagnostic criteria
to differentiate the disease from the colonization or contam-
ination. In fact, only 61% of patients were confirmed to have
≥2 positive cultures in this survey (21). After the mid-1990s,
the number of NTM isolates submitted to the Korean Insti-
tute of Tuberculosis for species identification dramatically
increased and exceeded 1000 isolates per year in recent years
(22). According to these results, MAC isolates were most
frequent in clinical specimens, followed by M. abscessus, and
M. fortuitum (22). 
The most useful study type with respect to addressing the
epidemiology of NTM pulmonary disease should combine
information from a mycobacterial laboratory and a clinician’s
assessment regarding to the presence or absence of disease,
because the isolation of an environmental NTM species from
a respiratory sample provides insufficient evidence concern-Diagnosis and Treatment of NTM Pulmonary Diseases 915
ing the presence of NTM pulmonary disease (8). Several
papers have detailed the relative frequencies of NTM isolates
in patients with clinically significant NTM pulmonary dis-
ease, by using microbiological and clinical data (Table 1) (14,
23-26). We recently performed a 2-yr study of 794 patients
with positive NTM cultures at the Samsung Medical Cen-
ter over 2002 and 2003 (26). Approximately one quarter of
patients with positive cultures were found to have clinical
lung disease. The most commonly involved organisms were
MAC (48%) and M. abscessus (33%) (26). This study con-
firms that MAC is the most common pathogen of NTM
pulmonary disease in Korea. However, contrary to many
other countries the second most common cause in Korea is
M. abscessus, and M. kansasii has remained a relatively uncom-
mon cause of NTM pulmonary disease. Actually, we report-
ed the first three cases of M. kansasii pulmonary disease in
immunocompetent patients in 2003 (27), and by using the
Korean Institute of Tuberculosis database from 1997 to 2002,
Yim et al. identified 15 patients with M. kansasii pulmonary
disease (28).
Fig. 1. M. intracellulare pulmonary disease of the upper lobe cavi-
tary form in a 73-yr-old man. Chest radiograph shows parenchy-
mal opacity which is containing multiple cavities in the right upper
lobe. Also note nodular lesions in left middle and lower lung zones
(A). Transaxial lung window CT image (2.5-mm section thickness,
70 mA) obtained at the level of the right upper lobar bronchus shows
dilated bronchi in an opacified right upper lobe. Also note associ-
ated multiple cavitary lesions (arrows). A lobular consolidative lesion
(arrowhead) is seen in the left upper lobe (B). Coronal reformation
(2.0-mm section thickness) image demonstrates dilated bronchi
and multiple thin walled cavities (arrows) in the right upper lobe.
Also note multiple variable-sized nodules and consolidation (arrow-
head) in the left lung (C).
A
C
B
Bai et al. (23) Lew et al. (24) Koh et al. (25) Lee et al. (14) Koh et al. (26)
Study period 1980-1990 1982-1991 2001.10-2002.3 2002.1-2002.12 2002.1-2003.12
No. of patients 59 29 42 72 195
M. avium complex 29 (49%) 19 (66%) 23 (55%) 40 (56%) 94 (48%)
M. intracellulare 18 22 56
M. avium 51 83 8
M. abscessus 10 (17%)* 4 (14%)* 12 (28%) 15 (21%) 64 (33%)
M. fortuitum 12 (20%) 5 (17%) 4 (10%) 11 (15%) 21 (11%)
M. kansasii - - 2 (5%) 2 (3%) 7 (3%)
Miscellaneous 8 (14%) 1 (3%) 1 (2%) 4 (5%) 9 (5%)
Table 1. Etiology of nontuberculous mycobacterial pulmonary disease in case series studies in Korea
*M. abscessus isolates were reported as M. chelonae complex without further species identification until 2000. Because M. chelonae is an extremely
rare cause of pulmonary disease, most respiratory isolates identified as M. chelonae complex can be reasonably assumed to be M. abscessus isolates. 916 W.-J. Koh, O.J. Kwon, K.S. Lee
CLINICAL PRESENTATION AND DIAGNOSTIC
CRITERIA
NTM organisms are commonly isolated from environmen-
tal sources, and thus their growths in culture raise the ques-
tion of specimen contamination. Moreover, even a finding
of mycobacteria in an uncontaminated clinical specimen
raises the question as to whether the isolate is the cause of
infection or disease. On the other hand, isolation from blood
or other sterile sites, along with the clinical manifestations
of the disease, is reasonable grounds for considering that an
NTM isolate is the causative agent. Decisions on diagnoses
are more complex in cases of pulmonary disease, because
respiratory secretions from patients with underlying lung
disease may be colonized by these organisms without overt
clinical manifestations. 
Thus, the presence of compatible symptoms and signs is a
necessary clinical criterion, with the reasonable exclusion of
other etiologies of pulmonary disease (2). However, the signs
and symptoms of NTM pulmonary disease are often vari-
able and nonspecific. Patients often present with a chronic
cough, productive sputum, and fatigue. NTM infection of
the lungs often occurs in the context of a preexisting lung
disease, especially chronic obstructive pulmonary disease,
bronchiectasis, pneumoconiosis, and previous tuberculosis.
As a result, the clinical manifestations of NTM pulmonary
disease are often similar to those of underlying disease (2).
Sometimes, it is very difficult to separate symptoms that may
be due to NTM infection from those that may be due to an
underlying disease that has increased the individual’s suscep-
tibility to NTM. 
The radiographic criteria required are the presence of infil-
Fig. 2. M. intracellulare pulmonary disease of the nodular bronchiectatic form in a 63-yr-old woman. Chest radiograph shows a multifocal
patchy distribution of small nodular clusters in both lungs (A). Transaxial lung window CT image (2.5-mm section thickness, 70 mA) obtained
at the level of basal trunk (B) show small centrilobular nodules and bronchiectasis in the right middle lobe and in the lingular division of the
left upper lobe. Also note small cavitating nodules and lobular consolidation in the left lower lobe.
A B
Fig. 3. M. abscessus pulmonary disease in a 49-yr-old woman. Chest radiograph shows multifocal patchy areas of small nodular clusters
in both lungs. Also note parenchymal opacity in the right middle lobe (A). Transaxial lung window CT image (2.5-mm section thickness, 70
mA) obtained at the basal trunk (B) show bronchiectasis and small centrilobular nodules or tree-in-bud opacities (arrows) in the right mid-
dle lobe and in the lingular division of the left upper lobe. Also note bronchiolitis of small centrilobular nodules and tree-in-bud opacities in
both lower lobes.
A Btrates, cavitation, or multiple nodules on plain chest radio-
graphs, and/or multiple small nodules of less than 10 mm
in diameter or multifocal bronchiectasis on high-resolution
computed tomography (HRCT) of the lungs (Fig. 1-4) (2).
The well-known radiographic features of NTM pulmonary
disease caused by MAC or M. kansasii are similar to those of
postprimary tuberculosis (29-33). In these classic upper lung
zone diseases, the most common findings are linear and nodu-
lar areas of increased opacity in the apical and posterior seg-
ments of the upper lobes. These opacities can progress or re-
main stable over many years. Cavitation occurs in many cases
and there is frequent pleural thickening (Fig. 1, 4). Recent
studies on HRCT of the chest have shown that many patients
with non-cavitary disease of the middle and lower lung zones
caused by NTM infection, show both multifocal bronchiec-
tasis and clusters of small nodules and branching linear struc-
tures are present (Fig. 2, 3) (34-39).
In the absence of the diagnostic specificities of clinical mani-
festations or chest radiographic findings, a diagnosis of NTM
pulmonary disease requires microbiologic confirmation. How-
ever, sputum cultures positive for NTM must be interpret-
ed cautiously. The discovery of NTM in a single sputum sam-
ple is not proof of NTM disease, especially when the AFB
smear is negative and NTMs are cultured in small numbers.
The distinctions between colonization, contamination, and
true infection are not always clear-cut for isolates from a given
individual. 
In 1997, the American Thoracic Society revised its diagnos-
tic criteria for NTM pulmonary disease (Table 2) (2). The
American Thoracic Society diagnostic criteria put much grea-
ter emphasis on multiple cultures and identification using
at least three sputum samples. HRCT and the invasive bron-
choscopic approach including bronchial washing and trans-
bronchial lung biopsy were recommended by the American
Thoracic Society, especially in patients without cavitary infil-
trates (2). 
Because NTM pulmonary disease can be indolent, the im-
portance of appropriate follow-up to determine the signifi-
cance of potentially pathogenic NTMs isolated from sputum
cannot be overemphasized. Delays in diagnosis are frequent,
and radiographs may remain unchanged for years. When
NTM cultures are positive, stable chest radiographic find-
ings, especially at relatively short intervals, are not sufficient
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Fig. 4. M. kansasii pulmonary disease in a 30-yr-old man. Chest radiograph shows cavitary and small nodular lesions in the left upper lobe
(A). Transaxial lung window CT thin-section images (1.0-mm section thickness, 170 mA) obtained at the thoracic inlet level show multiple
thin-walled cavities in the left upper lobe. Also note small nodular lesions and tree-in-bud opacities in the left upper lobe (B). 
A B
Clinical criteria
1. Compatible symptoms and signs
2. Reasonable exclusion of other disease
Radiographic criteria
1. Plain chest radiography
Infiltrates with or without nodules (persistent ≥2 months, or 
progression)
Cavitation
Nodules alone (multiple)
2. High-resolution computed tomography (HRCT)
Multiple small nodules
Multifocal bronchiectasis with or without small lung nodules
Bacteriologic criteria
1. If three sputum/bronchial wash results are available from the 
previous 12 months:
(1) Three positive cultures with negative AFB smear results, or
(2) Two positive cultures and one positive AFB smear
2. If only one bronchial wash is available:
(1) Positive culture with a 2+, 3+, or 4+ AFB smear, or 
(2) 2+, 3+, or 4+ growth on solid media
3. If sputum/bronchial wash evaluations are nondiagnostic or
another disease cannot be excluded:
(1) Transbronchial or lung biopsy yielding NTM, or
(2) Biopsy showing mycobacterial histopathologic features 
(granulomatous inflammation or AFB smear) and one or 
more sputa or bronchial washing procedures positive for 
NTM, even in low numbers
Table 2. Criteria for the diagnosis of nontuberculous mycobac-
terial lung disease in non-immunocompromised patients*
AFB, acid-fast bacilli; NTM, nontuberculous mycobacteria.
*reprinted with permission from American Thoracic Society (2).grounds to exclude true infection. In the absence of a lung
biopsy, months to years of clinical, radiographic, and micro-
biological follow-up may be required to reliably determine
the significance of NTM respiratory isolates (2).
LABORATORY METHODS 
In general, the AFB staining and culture techniques adopt-
ed for M. tuberculosis also work satisfactory for NTM. The
microscopic appearance of NTM is generally indistinguish-
able from that of M. tuberculosis. Thus, AFB seen on a smear
test may represent either M. tuberculosis or NTM. Therefore,
in regions with higher rates of NTM infection, such as the
United States, nucleic acid amplification (NAA) tests are rou-
tinely recommended to differentiate M. tuberculosis and NTM
in AFB smear-positive sputum samples (40).
NAA tests are also reported to be useful for the differenti-
ation of pulmonary tuberculosis and NTM pulmonary dis-
ease in patients with AFB smear-positive sputum in Korea
(41, 42). However, these tests cannot be routinely performed
in many laboratories in Korea, because they are expensive
and necessitate advanced facilities. Further studies are need-
ed to evaluate the clinical utility and cost-effectiveness of
applying NAA tests for the rapid differentiation of NTM
and M. tuberculosis in AFB smear-positive sputum samples
in Korea, especially in patients with specific risk factors of
NTM pulmonary disease, such as an advanced age or a pre-
vious history of pulmonary tuberculosis (17).
With regard to mycobacterial culture methods, it is now
recommended that, when possible, samples should be inoc-
ulated onto one or more solid medias (Lowenstein-Jensen or
Middlebrook 7H10 and 7H11) and into a liquid medium
(BACTEC, MGIT, ESP). The latter allows more rapid cul-
ture and the isolation of a greater range of species than does
solid media alone (2, 7, 40). The use of solid media as the
primary or sole means of culture is no longer recommended
in developed countries, such as the United States (2, 7, 40).
However, at present most microbiology laboratories in Korea
use only Lowenstein-Jensen solid media (43, 44), which is
an excellent medium for M. tuberculosis recovery, but is gen-
erally inferior to Middlebrook agar as an all-purpose medi-
um for both M. tuberculosis and NTM (2, 7, 40).
NTM organisms are identified by their patterns of pigmen-
tation, growth characteristics and microscopic appearances,
and by biochemical tests such as niacin production, nitrate
reduction, Tween-80 hydrolysis etc. However, this strategy
is time consuming and inconclusive for many isolates with
variable characters. More rapid discriminatory systems are
being developed; these include nucleic acid probe techniques,
polymerase chain reaction restriction enzyme analysis, high-
performance liquid chromatography, and nucleic acid sequenc-
ing (2, 7). Nowadays, polymerase chain reaction and restric-
tion fragment length polymorphism analysis (PRA) using
the rpoB gene or the hsp65 gene has been developed for use
in clinical practice in Korea (45, 46). 
Antimicrobial susceptibility testing of NTMs is both more
difficult and controversial than that of M. tuberculosis (2, 3).
In general, the results of standard susceptibility tests are of
little or no value in terms of predicting clinical efficacy in
cases of NTM infection, and the provision of in vitro suscep-
tibility results to clinicians is more likely to confuse rather
than help (2, 3). Currently, M. kansasii is routinely tested only
against rifampin, and MAC only against a newer macrolide
(usually clarithromycin), whereas rapidly growing mycobac-
teria are generally tested against multiple drugs (2, 3).
In clinical practice, unnecessary or inappropriate antituber-
culosis treatment has been instituted in many patients with
NTM pulmonary disease in Korea (17). Some patients have
even been treated for presumed multidrug-resistant tuber-
culosis (47, 48). We consider that this is probably related to
insufficient efforts being made to detect such patients, and
that this is mainly due to bacteriological testing practices.
In some laboratories, the specimen examination is limited
to direct sputum smear microscopy, whilst in other labora-
tories, even when culture isolation is a part of the routine
laboratory protocol, physicians may be unaware of the dif-
ferentiation of NTM and M. tuberculosis (43, 44). Another
major problem that may limit NTM recovery is that culture
isolation is performed only on an egg-based medium in the
majority of Korean laboratories, which is not an optimal choice
for NTM isolation (43, 44). In addition, in an area with a
high incidence of tuberculosis such as Korea, patients with
AFB smear-positive sputum and an abnormal chest radio-
graph are likely to be administered empiric antituberculosis
therapy, which is also partially active against MAC and highly
active against M. kansasii (2, 3). This makes attempts to obtain
further confirmatory isolates from patients with MAC or M.
kansasii disease less likely to be successful. A solution to these
problems would be of particular value to clinicians in Korea.
Mycobacterium avium COMPLEX LUNG DISEASE
The two species of MAC, i.e., M. avium and M. intracellu-
lare, are the most frequently encountered cause of NTM pul-
monary disease. Although they are distinct species and can
be identified and distinguished by using nucleic acid probes,
they are very similar phenotypically. Moreover, demograph-
ics, symptoms, radiographic features, and responses to ther-
apy are indistinguishable for patients infected with these two
species (2, 3). 
The symptoms and signs of MAC lung disease are variable
and nonspecific. In addition, the natural history of MAC
lung disease in HIV-negative patients is unpredictable. Some
patients maintain a stable clinical and radiographic picture
for years, whereas others experience rapid disease progression.
This feature appears to be related in part to the existence of
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. .
. .two types of clinical disease and presentation.
MAC lung disease has been recently differentiated into two
distinct subtypes, the upper lobe cavitary form and the nodu-
lar bronchiectatic form (2). The best known of these is upper
lobe cavitary lung disease which radiographically and clini-
cally mimics reactivation tuberculosis (Fig. 1). These patients
are predominantly middle-aged or elderly male alcoholics
and/or smokers with coexistent chronic obstructive pulmonary
disease. Chest radiography frequently demonstrates apical
cavitary change, similar to that seen in reactivated tubercu-
losis (29-33). Endobronchial disease spread is also common
and manifests as unilateral or bilateral scattered nodular areas
of increased opacity. Adenopathy and pleural effusion are
uncommon, though progressive fibrosis with volume loss
and traction bronchiectasis in the upper lobes occurs in one-
third of patients (29-33). This form of disease is generally
progressive, and if left untreated can lead to extensive lung
destruction and death (2).
A second clinical presentation, the so-called nodular bron-
chiectatic form, has recently been recognized (Fig. 2) (2).
These patients are predominantly nonsmoking middle-aged
or elderly women without previous or underlying lung dis-
ease (49, 50). The disease is often focused in the lingular and
right middle lobes, a feature referred to as Lady Windermere’s
syndrome (50). The lungs typically show nodular disease
and cylindrical bronchiectasis, often in the same lung seg-
ment. In the nodular bronchiectatic form, the isolation of
MAC from sputum specimens is less consistent than from
the upper lobe cavitary form. Sputum may be intermittently
positive or positive with low numbers of organisms (51).
Because of the high false-negative rates of sputum cultures
in such a population, bronchoscopy or lung biopsy is required
in many patients to diagnose active MAC infection (52). This
low sensitivity of sputum cultures may be the result of the
non-cavitary nature of the disease. Therefore, this type of
disease has often been referred to as airway ‘‘colonization’’ in
the past, and the real disease has been considered to be bron-
chiectasis (53). 
However, this concept has been continuously challenged.
Recent studies involving the use of HRCT scanning have
indicated that these patients show specific radiographic fea-
tures of parenchymal disease in addition to multifocal areas
of bronchiectasis. Typical HRCT findings are multiple small
nodules (<5 mm) and branching linear structures combined
with bronchiectasis in the same lobe of the lung, which are
usually confined to or most severe in the right middle lobe
and lingular segment of the left upper lobe (Fig. 2) (34-39).
In addition, some studies of biopsy specimens show granu-
lomatous inflammation, suggesting lung tissue invasion by
the organisms involved (38, 54, 55). Both HRCT and patho-
logic findings are considered to be due to the presence of
mycobacterial ‘‘disease’’, and the term ‘‘colonization’’ may,
therefore, be inappropriate (2). Patients with this new clini-
cal presentation of MAC lung disease account for approxi-
mately 50% of cases in Korea and in the United States and
Japan (47, 51, 56). 
Then, the appropriate distinction is not between coloniza-
tion and invasive disease but between those with nodular
bronchiectasis who require immediate therapy directed at
MAC, and those in whom such a decision can be delayed (2,
57, 58). Treatment requires careful assessment on an indi-
vidual basis, and the risks and benefits of therapy should be
weighed before starting. Specifically, one should recognize
that MAC lung disease may be present, but be only mini-
mally progressive over months or years. In such instances,
the strategy of prolonged treatment with multiple, poorly
tolerated antibiotics may be replaced by an observational
strategy. If a decision is made to observe such a patient, it is
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Organism
Drug
Doses Duration
Surgery
M. avium complex Clarithromycin 500 mg b.i.d. Until culture negative for 1 yr based on Consider resection for localized 
Rifampin 600 mg (450 mg, body weight <50 kg) monthly sputum cultures disease if isolate becomes 
Ethambutol 25 mg/kg for 2 mo, then 15 mg/kg macrolide resistance
±Streptomycin (dosing based on age, 
body weight, renal function) considered for 
severe/advanced disease
M. abscessus Clarithromycin 500 mg b.i.d. and Oral antibiotics for prolonged duration along  Consider resection for
Ciprofloxacin 500 mg b.i.d. and with parenteral antibiotics for initial 4 wk for localized disease
Doxycycline 200 mg b.i.d. and symptomatic and progressive disease
Amikacin 15 mg/kg and
Cefoxitin 200 mg/kg (max 12 g/d) or
Imipenem 750 mg t.i.d.
M. kansasii Isoniazid 300 mg 18 mo (culture negative at least 1 yr) Not routinely indicated
Rifampin 600 mg (450 mg, body weight <50 kg)
Ethambutol 25 mg/kg for 2 mo, then 15 mg/kg
Table 3. Treatment protocol for nontuberculous mycobacterial lung diseases (Samsung Medical Center)* 
b.i.d., twice daily; t.i.d., three times daily. *Adapted from the reference (2).incumbent upon the treating physician to continue collect-
ing respiratory specimens for AFB analysis and to follow-up
with chest radiographs and/or HRCTs over a relatively long
period of time, as MAC disease will probably progress at some
time. On the other hand, if progression is noted based on
clinical, radiographic, and microbiologic criteria, prompt
treatment will probably help stabilize symptoms, pulmonary
function, and radiographic abnormalities (2, 57, 58).
Historically, therapy for MAC lung disease, until the intro-
duction of macrolides, was only partially effective (2, 3). The
newer macrolides, clarithromycin and azithromycin, have
had a great impact on the treatment of this disease, and recent
studies show good in vitro and clinical results (59-61). For
the treatment of adults without HIV infection, the American
Thoracic Society recommended a daily regimen of clarithro-
mycin or azithromycin, with rifampin or rifabutin in com-
bination with ethambutol, and intermittent streptomycin
for the first 2 to 3 months of therapy was recommended for
extensive disease (2). We have typically prescribed initial
daily dosing with clarithromycin (500 mg twice a day), rifam-
pin (600 mg for body weight >50 kg, 450 mg for body weight
≤50 kg), and ethambutol (25 mg/kg per day for 2 months
followed by 15 mg/kg per day). Streptomycin has been used
in patients with radiographically extensive or cavitary disease,
especially when this is accompanied by strongly positive spu-
tum smears (Table 3) (62). Clarithromycin is likely to be
more effective than azithromycin, and rifampin is better tol-
erated than rifabutin (63). If intolerance evolves (typically
taste perversion or a gastrointestinal upset), the dose of clar-
ithromycin should be reduced or azithromycin substituted.
Toxicity screening should be performed to detect liver func-
tion abnormalities, visual changes, and hearing alterations.
Dose adjustments or the discontinuation of one or more anti-
biotics are frequently required on an individual basis. Gener-
ally, therapy should be continued until sputum cultures are
consecutively negative for at least one year (typically 18 to
24 months) (2). However, treatment success rates are unsat-
isfactory. If success is defined as eradication of the organism
without relapse over a period of several years after treatment
has been discontinued, the reported treatment success rate
for macrolide containing regimens is less than 60% (58).
Surgery may be useful in cases of localized disease, especially
upper lobe cavitary disease, if drug response is poor, if a pati-
ent’s isolate has become macrolide resistant, or if a patient is
drug intolerant (2). We reported the first Korean case of refrac-
tory MAC pulmonary disease treated successfully by surgery
in 2003 (64).
Routine susceptibility testing is unnecessary, as all untreat-
ed MAC isolates are macrolide susceptible (2, 3). For those
who do not respond or who relapse on clarithromycin or azi-
thromycin, susceptibility testing to these agents becomes
critical. In one study, sputum converted in only 25% of pati-
ents with strains that had resistance or intermediate sensi-
tivity to clarithromycin strains compared with 84% of pati-
ents with susceptible strains before treatment (61). No effec-
tive drug regimen for clarithromycin-resistant isolates has
been established. Alternative second-line agents include flu-
oroquinolone, cycloserine, ethionamide, clofazimine and pro-
longed use of streptomycin or amikacin (2, 57).
With regard to the macrolide resistance of MAC infections,
we are concerned about the current clinical practice used for
bronchiectasis treatment. In practice, macrolides have been
frequently used in Korea to treat patients with diffuse bron-
chiectasis (65), as prolonged treatment with low-lose erythro-
mycin has been reported to be effective in diffuse panbron-
chiolitis and in some cases of bronchiectasis (66). However,
we strongly recommend that the long-term use of low-dose
macrolide therapy in patients with diffuse bronchiectasis
should only be commenced after carefully considering and
evaluating the possibility of NTM pulmonary disease. This
rationale is recommended to avoid macrolide monotherapy
and the development of macrolide-resistant strains in patients
with MAC lung disease. HRCT findings in patients with
diffuse panbronchiolitis are similar to those reported for
patients with NTM pulmonary disease (34-39). We recently
demonstrated that NTM infection is the most common and
important cause of, or condition associated with, bilateral
bronchiectasis and bronchiolitis in Korean patients (39).
Mycobacterium abscessus LUNG DISEASE
The nomenclature used to describe rapidly growing myco-
bacteria has changed much and is a source of confusion for
clinicians. For instance, over the past 20 yr, M. abscessus, the
most common respiratory pathogen among the rapidly grow-
ing mycobacteria, has been labeled as M. cheloneii subspecies
abscessus, M. chelonae subspecies abscessus, and finally, in 1992,
as M. abscessus (67). Species identification is important because
therapy differs significantly depending on the rapidly grow-
ing mycobacteria species obtained.
M. abscessus accounts for approximately 80% of rapidly
growing mycobacterial pulmonary disease isolates, and M.
fortuitum accounts for 15% (68). Rarely, M. chelonae and other
rapidly growing mycobacteria are identified as respiratory
pathogens. Overall, M. abscessus appears to be a more virulent
respiratory pathogen than M. fortuitum (2, 67) and a single
respiratory isolate of M. abscessus is more likely to indicate
significant disease than a single isolate of M. fortuitum. In
addition, patients with multiple M. abscessus respiratory iso-
lates almost invariably have significant and progressive M.
abscessus pulmonary disease. However, even after obtaining
multiple M. fortuitum respiratory isolates, there may still be
doubt about the significance of these isolates in the absence
of a clear predisposing condition, such as achalasia or recur-
rent aspiration (67).
M. abscessus pulmonary disease patients tend to occur in
middle-aged or older, female nonsmokers (67, 68). Approx-
920 W.-J. Koh, O.J. Kwon, K.S. Leeimately 40% of patients have an underlying medical condi-
tion, such as prior mycobacterial infection, lipoid pneumonia,
or gastroesophageal disorders with chronic vomiting (67, 68).
Patients with the above risk factors often develop disease at
a younger age compared with patients without underlying
medical conditions (67). 
The most frequent patterns seen at chest radiography are
multilobar, patchy, reticulonodular or mixed interstitial-alve-
olar infiltrates. Cavitation occurs in less than 20% of patients.
The most common HRCT findings in patients with M. absces-
sus pulmonary disease are diffuse bronchiectasis, multiple
small lung nodules, focal areas of consolidation, and bronchial
wall thickening (Fig. 3) (69, 70), which are very similar to
those reported for MAC lung disease (38, 39). In most patients
with M. abscessus without an underlying disorder, the disease
progresses very slowly, and some patients show little radio-
graphic change over a period of years (67, 68).
M. abscessus pulmonary disease clinically and radiographi-
cally resembles MAC pulmonary disease, especially the nodu-
lar bronchiectatic form of MAC pulmonary disease (67, 70).
In addition, comparable percentages of patients with the
nodular bronchiectatic form of MAC infection or M. abscessus
infection also had M. abscessus or MAC, respectively, in spu-
tum (51, 68). Not surprisingly, it can be difficult to deter-
mine whether MAC or M. abscessus is the most important
pathogen in these patients. These findings suggest that the
risk factor for the two diseases may be similar. Studies by
Japanese investigators have demonstrated that the associa-
tion between specific human leukocyte-associated antigen
phenotypes and MAC lung disease could raise the possibility
of genetic defects in patients with NTM pulmonary disease
(71, 72). Recently, we found a significant association between
polymorphisms of NRAMP1 gene and the nodular bronchie-
ctatic form of NTM pulmonary disease caused by MAC or
M. abscessus (73). These findings suggested that a genetic sus-
ceptibility might play a role in the development of NTM
pulmonary disease. 
The antimicrobial susceptibility testing results of rapidly
growing mycobacteria differ from those of other NTMs. M.
abscessus, M. chelonae, and M. fortuitum are resistant to all anti-
tuberculosis drugs, including isoniazid, rifampin, ethambu-
tol, and pyrazinamide. Thus, routine susceptibility testing
to antituberculous drugs is not recommended (2, 67). How-
ever, they are susceptible to a number of traditional antibac-
terial agents. M. abscessus is usually susceptible to clarithro-
mycin, amikacin, and cefoxitin and is moderately susceptible
to imipenem. Thus, all clinically significant isolates should
be tested against selected antibacterial agents, such as, amikacin,
cefoxitin, imipenem, clarithromycin, ciprofloxacin, doxycy-
cline, and sulfamethoxazole (2, 67).
The optimal therapeutic regimens and treatment dura-
tion for M. abscessus pulmonary disease have not been estab-
lished. Clarithromycin was administered in a small study as
monotherapy for M. abscessus pulmonary disease, but was
found to be insufficient to produce microbiologic cure (74).
The American Thoracic Society recommends treating patients
with clarithromycin in combination with high-dose cefox-
itin and low-dose amikacin (2). This approach usually requires
the placement of long-term indwelling intravenous access,
and introduces the risk of attendant morbidity. Short cours-
es (2 to 6 weeks) of amikacin, cefoxitin, and clarithromycin
in combination can provide symptomatic, bacteriologic, and
radiographic improvements but may not be curative (2, 67).
Typically, we have treated patients with progressive M. absces-
sus pulmonary disease with long-term clarithromycin (1,000
mg/day), ciprofloxacin (1,000 mg/day), and doxycycline (200
mg/day) together with parenteral amikacin (15 mg/kg/day)
and cefoxitin (200 mg/kg/day) initially for the first four weeks
(Table 3) (75). Symptomatic and radiographic improvements
were observed in almost all patients, and negative sputum
conversion was achieved and maintained in about 60% of
patients for more than 6 months (75). Unfortunately, adverse
therapy-related reactions, such as leukopenia, thrombocytope-
nia, and hepatotoxicity were frequently observed which were
attributed to cefoxitin, and these necessitated changing to
imipenem in about 60% of patients during initial antibiotic
therapy (75). Unfortunately, the long-term consequences of
the above study are unclear.
The only reliably curative therapy for M. abscessus pulmonary
disease is surgical resection of the involved lung (67, 68).
Patients with focal lung disease who can withstand lung
resection should be treated surgically after an initial period
on antimicrobials to lessen the microbial burden. We also
reported on the successful surgical treatment of M. abscessus
pulmonary disease (76). Unfortunately, suppressive therapy,
including periodic parenteral antibiotic or oral macrolide
therapy, may be all that can be realistically administered to
control the symptoms and progression of this disease (2, 67).
Moreover, because M. abscessus pulmonary disease may show
little progression in many immunocompetent patients, a
decision to withhold treatment may be made in some patients.
For example, in an elderly patient with minimal symptoms
and noncavitary disease, the best approach may be to only
follow closely for evidence of more rapid progression instead
of immediately starting therapy (67). 
Mycobacterium kansasii LUNG DISEASE
Unlike other NTMs, M. kansasii is only rarely isolated
from natural water supplies (2, 6). Tap water is likely to be
the major source for M. kansasii causing human infections
and the organism has been isolated from tap water in com-
munities where patients with M. kansasii disease have been
identified. Previous studies have demonstrated that M. kansasii
cases are significantly more likely to come from urban than
rural areas, which supports a possible association between
clinical disease and the presence of the organism in potable
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The clinical and radiological features of pulmonary disease
caused by M. kansasii usually resemble those of pulmonary
tuberculosis (2, 3, 77) and is more likely to occur in older
men. Risk factors for M. kansasii infection include chronic
obstructive pulmonary disease, pneumoconiosis, previous
mycobacterial disease, malignancy, and alcoholism. Howev-
er, approximately 40% of immunocompetent patients with
M. kansasii pulmonary disease were found to have no identi-
fiable predisposing condition (77). Its chest radiographic
changes closely resemble those of reactivation pulmonary
tuberculosis. Many patients have fibronodular or fibrocavi-
tary upper lobe disease (Fig. 4), whereas the others may have
only noncavitary (nodular/bronchiectasis) infiltrates similar
to those in patients with MAC or M. abscessus pulmonary
disease (77). 
Untreated strains of M. kansasii are inhibited by rifampin,
isoniazid, ethambutol, ethionamide, streptomycin, clarithro-
mycin, and probably ciprofloxacin at concentrations readily
achievable in serum using usual therapeutic doses (2, 77).
The concentrations of antituberculous drugs used in suscep-
tibility testing were chosen for their usefulness with M. tuber-
culosis. Because M. kansasii is less susceptible to these drugs
in vitro (but still susceptible to achievable blood levels), some
isolates may be reported resistant to isoniazid at 0.2 or 1.0
g/mL and to streptomycin at 2.0  g/mL. These isolates are
susceptible to slightly higher drug concentrations, so that
laboratory reports of resistance to low concentrations of these
two drugs have no clinical or therapeutic significance as long
as a rifampin-containing regimen is being used. Thus, when
clinically indicated, isoniazid and/or streptomycin should
be used against M. kansasii regardless of the in vitro suscep-
tibility results (2, 77).
The use of single-drug concentrations of rifampin chosen
for susceptibility testing of M. tuberculosis has predictive clin-
ical value for M. kansasii. Then, all initial clinically signifi-
cant M. kansasii isolates should be tested against rifampin.
Moreover, as acquired rifampin resistance may develop dur-
ing therapy and because prior therapy history may not be
determinable, all initial isolates of M. kansasii and those from
patients with known prior therapy should be tested against
rifampin. Also, testing should be performed when a patient’s
sputum fails to convert from smear and/or culture positive
or when a relapse occurs during therapy (2, 77).
The recommended treatment regimen for patients whose
M. kansasii isolates are susceptible to rifampin, is a three-drug
combination of isoniazid, rifampin, and ethambutol (2, 77).
Medication is usually administered daily for 18 months with
a minimum of 12 months culture negativity. Sputum con-
version rates for rifampin-containing regimens are almost
100%, and treatment failure and long-term relapse rates are
low. Surgery is now considered to have no role in the man-
agement of routine pulmonary disease cases (2, 77). 
CONCLUSION
It is likely that the incidence of pulmonary disease caused
by NTM will continue to rise in Korea, although it should
be noted that changes in clinician awareness have increases
the numbers of investigations, and the availabilities of labo-
ratory methods, which allow the isolation and identification
of previously unnoticed organisms, have all certainly contribut-
ed to this trend. However, the incidences of NTM pulmonary
disease are also expected to rise because increasing propor-
tions of the population are aging or are subject to some type
of immunosuppression. It appears that most pulmonary physi-
cians will be increasingly challenged by this mysterious epi-
demic in the future.
Pulmonary diseases caused by NTM are highly complex
in terms of clinical presentation and management. The impor-
tant components for establishing a diagnosis of NTM pul-
monary disease are: 1) the patient must have a compatible
clinical presentation including the time course; 2) the radio-
graphic picture must be consistent with a diagnosis of NTM
pulmonary disease; and 3) there must be a clear demonstra-
tion that the NTM recovered is there either in sufficient num-
bers or in pulmonary tissue. It should be emphasized that
all three elements must be fulfilled to establish a diagnosis
of NTM pulmonary disease. 
Treatment varies depending on the infecting species. How-
ever, the decisions about the institution of treatment for NTM
pulmonary disease are never easy. Treatments require the use
of multiple drugs for 18 to 24 months, and thus are expen-
sive. Moreover, they frequently have significant side effects,
and are often not curative. Therefore, clinicians should be
confident that there is sufficient pathology to warrant pro-
longed, multidrug treatment regimens. In all of the situa-
tions, outcomes can be best optimized only when clinicians,
radiologists, and laboratories work cooperatively.
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